19 October 2015
As the artemisinin-based combination treatment (ACT) Consortium draws to a close, investigators are ready to present results from research conducted between 2007 and 2015 in African and Asian malaria-endemic countries.
The international research collaboration was set to answer key questions on malaria drug delivery, particularly to improve the targeting of, and access to ACTs, as well as their safety and quality. ACTs are the recommended treatment for Plasmodium falciparum,
the most dangerous form of malaria.
The ACT Consortium is running exhibition booth 408 at ASTMH. From Sunday 25 October, all delegates can collect the schedule of posters and presentations from consortium studies:
Click on the image to download the schedule
The ACT Consortium encourages all delegates to engage in Q&A activities at booth 408, by writing questions and answers related to malaria drug delivery.
The discussions will follow on from the consortium's new booklet summarising the 25 studies:
The booklet provides answers to the following questions:
Free copies in the three languages will be available at the exhibition booth.